Guardant Health, Inc. (NASDAQ:GH) Q4 2020 Earnings Conference Call February 24, 2021 5:00 PM ET Company Participants Carrie Mendivil - Investor Relations Helmy Eltoukhy - Co-Founder & Chief Executive Officer AmirAli Talasaz - Co-Founder & President Mike Bell - Chief Financial Officer Conference Call Participants Brian Weinstein - William Blair Tycho Peterson - JPMorgan Doug Schenkel - Cowen Puneet Souda - SVB Leerink Tejas Savant - Morgan Stanley Derik de Bruin - Bank of America Patrick Donnelly - Citi Dan ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 _____________________ FORM 10-K _____________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38683 _____________________ GUARDANT HEALTH, INC. (Exact Name of Registrant as Specified i ...

Guardant Health, Inc. (NASDAQ:GH) Q3 2020 Results Earnings Conference Call November 5, 2020 4:30 PM ET Company Participants Carrie Mendivil - IR Helmy Eltoukhy - Co-Founder & CEO AmirAli Talasaz - Co-Founder & President Derek Bertocci - CFO Conference Call Participants Puneet Souda - SVB Tycho Peterson - JPMorgan Doug Schenkel - Cowen Derik de Bruin - Bank of America Brian Weinstein - William Blair Patrick Donnelly - Citi Tejas Savant - Morgan Stanley Sung Ji Nam - BTIG Operator Ladies and gentlemen, thank ...

Revenue Performance - Total revenue for the three months ended March 31, 2020, was $67,510,000, representing a 84.3% increase from $36,655,000 in the same period of 2019[17] - Revenue from precision oncology testing was $60,246,000, up from $28,837,000, indicating a growth of 109.1% year-over-year[17] - Revenue from the United States was $64.6 million for the three months ended March 31, 2020, compared to $31.2 million in 2019, indicating a 106.5% increase[136] Net Loss and Financial Position - The net loss for the three months ended March 31, 2020, was $31,829,000, compared to a net loss of $21,351,000 for the same period in 2019, reflecting an increase in losses of 49.5%[19] - The company reported a comprehensive loss attributable to Guardant Health, Inc. of $21,135,000 for the three months ended March 31, 2020[19] - For the three months ended March 31, 2020, the net loss attributable to common stockholders was $27.7 million, compared to a net loss of $26.1 million for the same period in 2019[133] Cash and Assets - Cash and cash equivalents increased to $152,239,000 from $143,228,000, showing a growth of 6.9%[14] - Total current assets as of March 31, 2020, were $607,392,000, a slight increase from $597,358,000 as of December 31, 2019[14] - As of March 31, 2020, the company had cash and cash equivalents of $152.2 million as of March 31, 2020, with short-term marketable securities of $367.9 million and long-term marketable securities of $238.2 million[242] Expenses - Research and development expenses increased to $37,016,000 from $16,316,000, marking a 126.6% rise year-over-year[17] - Net cash used in operating activities was $13,282,000 for Q1 2020, compared to $4,303,000 in Q1 2019, indicating a significant increase in cash outflow[25] - Operating lease expense for Q1 2020 was $1.5 million, compared to $0.8 million in Q1 2019, reflecting a 87.5% increase[106] Stock and Equity - The weighted-average shares used in computing net loss per share attributable to common stockholders increased to 94,382,000 from 85,935,000 year-over-year[17] - The total stockholders' equity as of March 31, 2020, was $785,113,000, down from $798,393,000 as of December 31, 2019[14] - Stock-based compensation expense for Q1 2020 totaled $6.34 million, compared to $3.18 million in Q1 2019, representing a 99.4% increase[119] Joint Venture and Collaborations - The Company consolidated the Joint Venture's financial position, results of operations, and cash flows in its financial statements[78] - The company collaborates with pharmaceutical companies for drug development, generating revenue from milestone achievements and ongoing support[54] - The Company entered into a settlement and patent license agreement with KeyGene on March 10, 2020, resolving a prior arbitration without an award[112] Future Expectations and Plans - The company believes its existing cash and cash equivalents will be sufficient to fund its current operating plan for at least one year[32] - The company expects to recognize substantially all remaining transaction price allocated to performance obligations in the next 12 months[61] - The company is focused on developing tests for early-stage cancer patients through its LUNAR program, aiming to expand its product offerings[29] Accounting and Financial Reporting - The Company adopted ASU 2018-15 regarding cloud computing arrangements on January 1, 2020, with no significant impact on financial statements[73] - The Company early adopted ASU 2019-12 for income taxes on January 1, 2020, simplifying tax accounting without significant impact on financial statements[76] - The company did not recognize any credit losses in the three months ended March 31, 2020, as it intends to hold all marketable securities until maturity or recovery[96]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 _____________________ FORM 10-Q _____________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 GUARDANT HEALTH, INC. (Exact Name of Registrant as Specified in its Charter) _____________________ (State or other jurisdiction of incorporation or organization) 505 Penobscot Dr. For the quarterly period ended September 30, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 _____________________ FORM 10-Q _____________________ (Mark One) OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38683 _____________________ GUARDANT HEALTH, INC. (Exact Name of Registrant as Specified in its Charter) _____________________ x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 _____________________ FORM 10-K _____________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38683 _____________________ GUARDANT HEALTH, INC. (Exact Name of Registrant as Specified i ...